Navigation Links
Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
Date:3/20/2009

SOUTH SAN FRANCISCO, Calif., March 20 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will concentrate its cash resources on the clinical and commercial development of its late-stage oncology candidate, picoplatin. As a result, the Company has discontinued its in-house preclinical research operations and reduced its workforce by approximately 12 percent, or eight employees, effective March 31, 2009. The Company continues to evaluate strategic alternatives for its preclinical research programs.

"Concentrating our resources on advancing our lead product candidate, picoplatin, currently in Phase 2 and 3 clinical trials for the treatment of lung, colorectal and prostate cancers, supports our goal of commercializing picoplatin in 2010, initially for the treatment of small cell lung cancer," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We believe these measures will bring us closer to near-term success and build shareholder value. I would like to thank the Poniard employees who have been affected by this change for their significant contributions to the Company."

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of in
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
2. Poniard Pharmaceuticals Receives Going Concern Qualification
3. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
6. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Announces Upcoming Conference Participation
8. Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
9. Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potentcy Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
10. Endo Pharmaceuticals Announces Successful Completion of Tender Offer for Indevus Pharmaceuticals
11. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- People with the ... condition called peripheral artery disease (PAD), a new study suggests. ... supply blood to the limbs, most often the legs. The ... narrowing of the arteries throughout the body. People with PAD ... Researchers analyzed data from nearly 6,800 people with PAD who ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... News) -- U.S. health officials have concluded that it,s ... anthrax during a safety mishap last month. But, ... have announced a moratorium on the transfer of any ... In a report issued Friday, the CDC outlined several ... similar incident doesn,t occur again. Last month, as many ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... kids is almost a nightmare to their respective parents, ... Researchers identified three factors that may increase a child's ... the disease that does not respond to commonly used ... before their first birthday which is also called symptomatic ...
... Female sexual dysfunction is associated with loss of libido, ... who have attained their menopause or whose ovaries had ... serve as an effective treatment in such sexual dysfunction, ... meeting of the American Urological Association in Anaheim, California. ...
... to improve sexual function among the hypertensive men with ... is the disease process itself, probably from reduced vascular ... a study evaluated hypertensive men with erectile dysfunction and ... 7.3% before losartan therapy to 58.5 % after losartan ...
... the current New England Journal of Medicine that an experimental ... men suffering from hemophilia. This method shows signs of ... clotting protein they lack. None of the patients suffers ... ,The study was designed only to test the safety and ...
... high doses of vitamin E may help fight diabetes. ... the world with many ravaging complications, affecting millions of ... damage, kidney failure, non healing ulcers all over the ... system. ,Diabetes is caused by the deficiency of ...
... latest mantra of Pfizer. The pharmaceutical giant has announced ... hardest hit by the AIDS virus. The decision by the ... Government winning a landmark case against pharmaceutical companies. In ... Diflucan will be given free of cost to battle HIV ...
Cached Medicine News:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
... Accutest H. pylori WB test ... the qualitative detection of lgG ... in human whole blood. This ... an aid in the diagnosis ...
... OraQuick is an FDA approved ... whole blood test used to ... HIV-1 infection. This CLIA waived ... of antibodies to HIV-1, requires ...
... is designed to detect the IgM ... whole blood. The QuickVue+ Infectious Mononucleosis ... erythrocytes which give a greater sensitivity ... from sheep and horse erythrocytes. QuickVue+ ...
... point-of-care diagnostic test that can reliably and ... and B. The test uses a unique ... assists viral replication by promoting the release ... ZstatFlu substrate is labeled with a chromagen. ...
Medicine Products: